Chemical Works of Gedeon Richter Plc (RGEDF)
43.76
+0.45
(+1.04%)
USD |
OTCM |
Aug 25, 16:00
Chemical Works of Gedeon Richter EPS Diluted (Quarterly) : 0.6729 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6729 |
| March 31, 2026 | 1.090 |
| December 31, 2025 | 1.137 |
| September 30, 2025 | 0.6993 |
| June 30, 2025 | 0.7942 |
| March 31, 2025 | 0.9694 |
| December 31, 2024 | 0.9178 |
| September 30, 2024 | 0.5661 |
| June 30, 2024 | 1.058 |
| March 31, 2024 | 1.043 |
| December 31, 2023 | 0.5599 |
| September 30, 2023 | 0.841 |
| June 30, 2023 | 0.4529 |
| March 31, 2023 | 0.583 |
| December 31, 2022 | -0.3593 |
| September 30, 2022 | 1.107 |
| June 30, 2022 | 1.136 |
| March 31, 2022 | 0.6136 |
| December 31, 2021 | 0.7851 |
| September 30, 2021 | 0.6854 |
| June 30, 2021 | 0.5133 |
| March 31, 2021 | 0.483 |
| December 31, 2020 | 0.3842 |
| September 30, 2020 | 0.4017 |
| June 30, 2020 | 0.5314 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.5069 |
| December 31, 2019 | -0.2626 |
| September 30, 2019 | 0.4047 |
| June 30, 2019 | 0.3277 |
| March 31, 2019 | 0.4223 |
| December 31, 2018 | -0.3121 |
| September 30, 2018 | 0.1703 |
| June 30, 2018 | 0.4881 |
| March 31, 2018 | 0.3083 |
| December 31, 2017 | 0.136 |
| September 30, 2017 | 0.3249 |
| June 30, 2017 | 0.1598 |
| March 31, 2017 | 0.3827 |
| December 31, 2016 | 0.4179 |
| September 30, 2016 | 0.2762 |
| June 30, 2016 | 0.3387 |
| March 31, 2016 | 0.2226 |
| December 31, 2015 | 0.1855 |
| September 30, 2015 | 0.1318 |
| June 30, 2015 | 0.4372 |
| March 31, 2015 | 0.2952 |
| December 31, 2014 | -0.0931 |
| September 30, 2014 | 0.1273 |
| June 30, 2014 | 0.3317 |
| March 31, 2014 | 0.2225 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AstraZeneca PLC | 0.9849 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Avadel Pharmaceuticals Plc | 0.0002 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 122.85M |
| Revenue (Quarterly) | 777.18M |
| Total Expenses (Quarterly) | 653.98M |
| Enterprise Value | 7.165B |
| Gross Profit Margin (Quarterly) | 70.03% |
| Profit Margin (Quarterly) | 15.81% |
| Earnings Yield | 8.23% |
| Operating Earnings Yield | 12.53% |
| Normalized Earnings Yield | 8.226 |